Interleukin-4¹¹ Interleukin-4
IL-4 is the master Th2 cytokine secreted by activated CD4+ T cells, mast cells, basophils, and innate lymphoid cells type 2 (ILC2s); it drives naïve T cell polarization toward the Th2 phenotype, instructs B cells to switch antibody class to IgE, and maintains mast cell and eosinophil survival is the central regulator of the allergy-prone immune state. The IL4 gene sits on chromosome 5q31.1, a region long known to harbour susceptibility loci for atopic disease. rs2070874 is a C-to-T substitution 33 bases into the 5'-untranslated region (5'-UTR) of the IL4 transcript — between the transcription start site and the protein-coding start codon. At this position, the variant does not change the IL-4 protein but alters the RNA sequence in a way that influences how efficiently the mRNA is translated and, indirectly, how much IL-4 protein is ultimately produced.

The Mechanism

The 5'-UTR is not silent. It contains secondary structures (hairpin loops, internal ribosome entry elements, and upstream open reading frames) that regulate ribosome access and translation efficiency. A single-nucleotide change in this region can flatten or deepen a hairpin that otherwise impedes ribosomal scanning, raising the rate at which ribosomes reach the main IL-4 coding sequence. The T allele at position +33 is associated with higher IL-4 plasma levels in genotype-stratified studies — an association documented in multiple genotype-stratified studies — T allele carriers consistently show higher in-vivo IL-4 plasma levels than CC homozygotes, a relationship that is amplified when the T allele at this 5’-UTR site co-occurs with the IL4 VNTR allele-1 on the same haplotype (Bibert et al., Immunogenetics 2015²² (Bibert et al., Immunogenetics 2015
doi:10.1007/s00251-015-0836-3). The rs2070874 variant is also in strong linkage disequilibrium with rs2243250, the -589C>T promoter SNP. The two variants co-segregate on the same haplotype — the T alleles at both sites tend to be inherited together, and together they confer higher IL-4 transcription (rs2243250 effect via NFAT-1 binding) plus potentially higher translation efficiency (rs2070874 5'-UTR effect). The combined haplotype represents the most biologically active IL-4 configuration.

The Evidence

The strongest evidence for rs2070874 comes from a 2020 meta-analysis of 24 publications³³ 2020 meta-analysis of 24 publications
Imani et al., BMC Medical Genetics — 28 studies pooling 6,587 asthma cases and 8,408 controls with searches in Web of Science, Scopus, and PubMed. In the overall population, the T allele was a significant risk factor under all genotype models tested. Ethnicity- specific analysis found the association significant in Europeans across all models except heterozygote comparison, and in Americans and Asians across several models. Age-stratified analysis confirmed T allele risk in pediatric, adult, and mixed-age cohorts under the allelic model. An earlier 2014 meta-analysis⁴⁴ 2014 meta-analysis
Zheng et al. independently confirmed the -33C/T polymorphism as an asthma risk factor across ethnically diverse studies.

For atopic dermatitis, a 2016 pediatric case-control study⁵⁵ 2016 pediatric case-control study
Saadat et al., Allergy Asthma Immunol Res found that IL-4 gene polymorphisms including rs2070874 contribute to elevated atopic dermatitis risk in children, with T allele carriers showing higher serum IL-4 levels. The direct IgE link was established in early work by Howard et al. 2001⁶⁶ Howard et al. 2001, who associated the C+33T polymorphism directly with elevated total serum IgE in atopic cohorts.

Beyond classic atopy, a 2022 haplotype analysis⁷⁷ 2022 haplotype analysis
Junta et al., Genes of 195 patients demonstrated that the IL4 haplotype containing the rs2070874 T allele was significantly associated with NSAID-exacerbated respiratory disease (AERD/N-ERD) — the severe aspirin-sensitive asthma phenotype defined by nasal polyps, eosinophilic inflammation, and reactions to COX-1 inhibitors. This finding extends the IL4 5'-UTR variant's clinical footprint from common atopy to the most refractory eosinophilic asthma phenotype.

Evidence level: strong. Meta-analyses replicate across multiple ethnicities, ages, and atopic disease phenotypes; the biology (5'-UTR regulation of translation, plasma IL-4 elevation, serum IgE elevation) is mechanistically coherent.

Practical Actions

For T allele carriers, the elevated IL-4 output means: (1) total serum IgE is a directly informative biomarker — T allele carriers' IgE trends higher, and periodic measurement reveals whether the IL-4 pathway is biologically active; (2) quercetin and related flavonoids suppress IL-4 and IL-13 gene transcription in activated T cells with mechanistic specificity to this pathway; (3) for TT homozygotes with active moderate-to-severe atopic disease, dupilumab (which blocks the IL-4Rα receptor used by both IL-4 and IL-13) is the biologically best-matched therapy; (4) aspirin and NSAIDs warrant caution in T allele carriers with asthma, given the haplotype association with NSAID-exacerbated respiratory disease.

Interactions

rs2070874 is in strong linkage disequilibrium with rs2243250 (IL4 -589C>T) — the two T alleles co-segregate on the same haplotype. Carriers of both T alleles have the highest constitutive IL-4 output from combined promoter-level (NFAT-1 binding enhancement) and 5'-UTR-level (translation efficiency) effects. Haplotype-level analysis consistently shows stronger disease associations for the T/T haplotype at both sites than for either variant alone.

The rs1801275 variant (IL-4Rα Arg576Gln) alters the cytoplasmic signalling domain of the shared IL-4/IL-13 receptor chain. When elevated IL-4 production (rs2070874 T allele) meets altered receptor signal transduction (rs1801275), Th2 pathway output may be doubly amplified — a biologically plausible interaction that is relevant to dupilumab pharmacogenomics.

The rs20541 variant (IL-13 Arg130Gln) elevates IL-13 output through a separate gene but shares the IL-4Rα signalling chain. Carriers of both rs2070874-T and rs20541-A face combined Th2 cytokine over-activity from both arms of the IL-4/IL-13 axis — the combination that dupilumab is designed to block at the receptor level.

This SNP sits in an intron of MTR, the gene encoding methionine synthase — the enzyme that uses vitamin B12 as a cofactor to remethylate homocysteine back to methionine. Unlike the well-known missense variant rs1805087 (MTR A2756G / D919G), rs2275565 does not change the amino acid sequence of the enzyme. Instead, it appears to act as a regulatory variant that modestly shifts MTR expression or splicing and, as a consequence, influences how efficiently the one-carbon cycle runs under B12 and folate stress.

The Mechanism

rs2275565 is a G>T change on the plus strand at chr1:236885376 (GRCh38), located within an MTR intron across multiple transcript variants ¹¹ The variant is annotated as an intron variant by Ensembl VEP and as benign by ClinVar, but observational studies repeatedly link the T allele to higher plasma homocysteine. Because it is intronic it has no direct effect on the methionine synthase protein sequence. The most likely mechanism is a small effect on transcription, splicing, or mRNA stability that reduces enzyme abundance at the margin — enough to matter when B12 or folate supply is limited, but too subtle to show up in well-nourished cohorts.

The Folate/B12 Pathway Context

MTR sits at the convergence of the folate and B12 cycles. It takes a methyl group from 5-methyltetrahydrofolate (produced by MTHFR) and transfers it to homocysteine via a methylcobalamin intermediate. When MTR output drops, two things happen at once: homocysteine builds up, and methylfolate accumulates unusably — the so-called "methyl-folate trap" ²² Methylfolate can only donate its methyl group through MTR; when MTR is slow, methylfolate traps the folate pool in an unusable form. Because rs2275565 is a quantitative tweak rather than a missense hit, its phenotype is most visible when other pressures are in play: low B12 intake, competing MTHFR or MTRR variants, oxidative stress, or pregnancy.

The Evidence

The strongest recent signal comes from a Chinese case-control study³³ Chinese case-control study
Liu et al. Association of MTR gene polymorphisms with non-syndromic congenital heart disease. Scientific Reports, 2023 of 620 infants with non-syndromic congenital heart disease versus 620 controls. The TT genotype was associated with a roughly 5-fold increased risk of CHD (aOR 4.93, 95% CI 1.93–12.58), and the heterozygous GT genotype with a ~1.5-fold increase. This fits the broader pattern in which maternal one-carbon metabolism disturbances raise developmental risk for neural tube and cardiac defects.

Homocysteine findings are more mixed. The NHLBI Family Heart Study⁴⁴ NHLBI Family Heart Study
Jacques et al. Effects of MTR and MTRR polymorphisms on total plasma homocysteine, Atherosclerosis 2003 (n=677) found no significant effect of MTR variants on fasting plasma homocysteine but a trend toward higher post-methionine-load homocysteine in carriers. Overall the evidence level is moderate: the biological direction is consistent (T allele → more stress on the B12/folate cycle), but effect sizes in well-nourished populations are small and not all studies replicate.

Practical Actions

For T allele carriers, the practical move is to keep B12 status unambiguously generous — this is the cofactor MTR can't do without. Methylcobalamin or hydroxocobalamin are preferable to cyanocobalamin because they bypass a reduction step. Pairing with methylfolate (rather than synthetic folic acid) is the standard complement when there are also MTHFR variants present. Periodic homocysteine testing gives an objective readout of whether the cycle is running cleanly.

Interactions

rs2275565 is most meaningful when stacked with other one-carbon variants: rs1805087 (MTR D919G, the missense MTR variant), rs1801394 (MTRR A66G, which handles B12 reactivation), and rs1801133 (MTHFR C677T, the upstream methylfolate producer). A person heterozygous at rs2275565 alone is typically fine; a person with MTHFR TT plus one or both MTR hits benefits from more deliberate B12 and methylfolate support.

The SNCA gene¹¹ SNCA gene
Alpha-synuclein (SNCA) encodes the protein that aggregates into Lewy bodies — the pathological hallmark of Parkinson's disease; the gene harbors multiple independent risk variants spread across its genomic structure is bounded at its 5′ end by a regulatory landscape that controls how much alpha-synuclein the cell produces. rs2583988 sits approximately 1.4 kilobases upstream of the SNCA transcription start site — a "near gene-5" position that places it within the promoter-adjacent regulatory territory and within an intron of SNCA-AS1, the antisense long non-coding RNA that occupies the same chromosomal locus.

Unlike the other three SNCA variants in this database (rs356219, rs2736990, and rs11931074), rs2583988 has the weakest independent evidence of the group. Its primary clinical value is as the fourth component of the 4-SNP SNCA risk haplotype²² 4-SNP SNCA risk haplotype
The haplotype T-rs2583988 + G-rs356219 + C-rs2736990 + T-rs11931074 was identified in a 2017 Brazilian study as a high-risk combination, OR 2.51 for PD (Campelo et al. 2017) — the same haplotype documented in the studies that profiled its three companion SNPs. However, the TT homozygous genotype at rs2583988 does show a striking independent association (OR 12.20) in the Campelo cohort, and the T allele independently associates with cognitive impairment in PD patients.

The Mechanism

rs2583988 is classified as an upstream transcript variant³³ upstream transcript variant
A genomic variant in the region just 5′ of a gene's transcription start site, within or adjacent to promoter and enhancer elements that control gene transcription relative to SNCA. The position is within the 5′ regulatory zone that is known to control SNCA transcriptional output. Despite this location, a study measuring SNCA mRNA levels in peripheral blood mononuclear cells found no statistically significant correlation between rs2583988 genotypes and SNCA expression — suggesting that the variant may operate through a more nuanced regulatory mechanism rather than direct quantitative effects on transcript levels.

The most distinctive feature of rs2583988 is its unique association with the repressive histone mark H3K27me3⁴⁴ unique association with the repressive histone mark H3K27me3
H3K27me3 is placed by Polycomb repressive complex 2 (PRC2) and is associated with facultative heterochromatin — chromatin that can switch between active and silenced states at the SNCA upstream locus. Among the panel of SNCA PD risk variants studied in a 2019 epigenomics analysis, rs2583988 was the only variant showing this specific correlation. H3K27me3 marks so-called "bivalent chromatin" — regions poised to adopt either active or repressed states — suggesting that rs2583988 may influence SNCA expression through epigenetic chromatin remodeling rather than direct transcription factor binding disruption. The T risk allele may destabilize the repressive H3K27me3 state, potentially allowing SNCA to shift toward higher expression under specific cellular or environmental conditions.

The Evidence

The primary source for rs2583988's individual risk association is the 2017 Brazilian case-control study⁵⁵ 2017 Brazilian case-control study
Campelo et al. Variants in SNCA gene are associated with Parkinson's disease risk and cognitive symptoms in a Brazilian sample. Frontiers in Aging Neuroscience, 2017 (104 PD cases, 98 controls). The T allele was present in 28.8% of cases versus 19.3% of controls. The TT homozygous genotype showed a striking individual association of OR 12.20 (95% CI 1.52–97.58; p=0.018), and in multivariable logistic regression including environmental and clinical factors, the TT genotype predicted PD with OR 16.25 (95% CI 1.72–152.97; p=0.015). However, TT homozygotes were rare — only 11 cases and 1 control — making this estimate statistically unstable with very wide confidence intervals. The T allele was also significantly more common in PD patients with cognitive impairment (31%) than in controls (16%), yielding OR 2.39 (95% CI 1.25–4.58; p=0.010).

The same study identified the 4-SNP risk haplotype (T-rs2583988 + G-rs356219 + C-rs2736990 + T-rs11931074) with OR 2.51 (95% CI 1.37–4.58; p=0.003), establishing rs2583988 as an integral component of the highest-risk SNCA haplotype block.

A 2018 comprehensive meta-analysis⁶⁶ 2018 comprehensive meta-analysis
Zhang et al. A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson's Disease. Frontiers in Molecular Neuroscience, 2018 pooling data from 24,075 cases and 22,877 controls found rs2583988 T allele OR of 1.21 (95% CI 1.08–1.35; p=0.001) — statistically significant but below the p<1×10⁻⁵ threshold used to designate the strongest SNCA variants. The most recent 2025 systematic review⁷⁷ 2025 systematic review
Mohammadi et al. Common SNCA Genetic Variants and Parkinson's Disease Risk: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2025 across 27 studies found that rs2583988 showed only marginal significance under the allelic model, with the effect losing significance after sensitivity analysis and correction for publication bias — the weakest independent signal among the four haplotype-component variants. The evidence for rs2583988 as an independent PD risk factor is therefore rated as emerging.

A 2009 Saskatchewan cohort study⁸⁸ 2009 Saskatchewan cohort study
Heckman et al. Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population. Movement Disorders, 2009 (452 PD cases, 245 controls) found only a trend-level association between rs2583988 variation and rapid PD progression — not reaching statistical significance as an individual susceptibility marker.

Practical Actions

Given the emerging-level independent evidence and the tight linkage of rs2583988 with its three companion SNPs in the risk haplotype, the practical actions for T-allele carriers mirror those of the other SNCA risk variants: protecting the cellular environment against the downstream consequences of elevated alpha-synuclein, regardless of which upstream regulatory mechanism is responsible.

For TT homozygotes — who showed the most striking individual association in the Campelo study — the priority is the same neuroprotective strategy applied to the other high-risk SNCA genotypes: mitochondrial support with ubiquinol, autophagy promotion through aerobic exercise, manganese avoidance, and earlier neurological monitoring. The cognitive impairment association (OR 2.39 in PD patients with the T allele) adds weight to monitoring cognitive trajectory.

The T allele's extremely low frequency in East Asian populations (~1%) means this variant has almost no clinical relevance in that ancestry group — its clinical significance is concentrated in European populations where ~25% carry at least one T allele.

Interactions

rs2583988 is the 5′-upstream component of the 4-SNP SNCA risk haplotype⁹⁹ 4-SNP SNCA risk haplotype alongside rs356219 (3′ regulatory), rs2736990 (intron 4), and rs11931074 (3′ UTR). These four variants occupy different linkage disequilibrium blocks across the SNCA locus and carry independent risk information. The combined haplotype T+G+C+T has OR 2.51 — substantially higher than any single variant alone — confirming that multi-SNP SNCA risk assessment is more informative than evaluating any single variant in isolation.

The companion variants are each independently profiled in this database: rs356219 (strong independent evidence, SNCA expression elevation), rs2736990 (strong independent evidence, intron 4 regulatory), and rs11931074 (strong independent evidence, 3′ UTR mRNA stability). Together they provide comprehensive coverage of the SNCA PD risk locus.

The CYP2D6 gene metabolizes roughly 25% of all prescribed medications, including opioid pain relievers, antidepressants, antipsychotics, and cardiovascular drugs. Its highly polymorphic sequence — over 150 star alleles catalogued — means that careful variant-level characterization is essential for accurate pharmacogenomic interpretation. rs28695233 is an intronic variant at position chr22:42,130,558 (GRCh38), located 53 base pairs downstream of exon 2 in the deep intronic region of CYP2D6 (HGVS: NM_000106.6:c.180+53T>G). The alternate G allele appears at approximately 8% globally in the gnomAD v4 exome dataset.

The Variant in Context

CYP2D6 star alleles are defined by combinations of variants — core variants that alter protein function (by affecting splicing, amino acid sequence, or expression), and sub-allele variants that serve as haplotype markers for specific lineages of the gene without independently changing enzyme activity. The Pharmacogene Variation Consortium (PharmVar)¹¹ Pharmacogene Variation Consortium (PharmVar)
PharmVar maintains the authoritative CYP2D6 star allele nomenclature database at definitive, moderate, and limited evidence levels has catalogued rs28695233 as a sub-allele tag at the [definitive evidence level | definitive: the variant has been confirmed by multiple validated methods and appears in one or more named sub-alleles within the PharmVar database].

Intronic variants 50+ base pairs from splice sites are generally too distal to disrupt canonical splicing, and no published study has demonstrated that rs28695233 alone alters CYP2D6 mRNA processing, protein expression, or metabolic activity. Importantly, it is absent from ClinVar and carries no pharmacogenomic annotation in PharmGKB independent of the haplotype context that defines its sub-allele.

Why It Gets Catalogued

The practical reason sub-allele variants like rs28695233 receive detailed cataloguing is genotyping assay interference. Clinical CYP2D6 allele-calling relies on targeted probes or amplicons designed against specific loci. An unexpected variant at or near a probe target can cause probe dropout, allele imbalance, or ambiguous calls — which a laboratory might misinterpret as a different star allele. By cataloguing sub-allele variants, PharmVar enables laboratories to recognize when an unusual signal is a known background variant rather than a new functional mutation. Pratt et al. 2021²² Pratt et al. 2021
Pratt VM et al. Recommendations for Clinical CYP2D6 Genotyping Allele Selection. J Mol Diagn, 2021 note that sub-allele variants lacking functional consequences are nonetheless important for ensuring accurate assay performance in clinical labs.

The Evidence

No published study has demonstrated an independent pharmacogenomic effect of rs28695233. The CYP2D6 activity score system³³ CYP2D6 activity score system
Gaedigk A et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of CYP2D6 function. Clin Pharmacol Ther, 2008 assigns activity scores based on the core star allele definition, not individual sub-allele variants — meaning rs28695233's presence or absence does not change the CPIC-assigned metabolizer phenotype of the haplotype it rides on.

The most functionally characterized intronic CYP2D6 variants that affect splicing and expression are: rs3892097 (CYP2D6*4, intron 3 splice site, abolishes function), rs28371725 (CYP2D6*41, intron 6, 2988G>A, reduces splicing efficiency ~50%), and rs1058164 (exon 3 synonymous, promotes exon 3 skipping). These have direct, measured functional consequences. rs28695233, by contrast, sits in intron 2 at a deep position (c.180+53) where there is no published evidence of analogous splicing disruption.

Practical Significance

For individuals who receive a clinical CYP2D6 report that mentions rs28695233, the key point is that this variant's haplotype context — not the variant itself — determines the clinical interpretation. The sub-allele carrying this G allele will have a defined star allele designation (e.g., a specific *1 or *2 sub-allele) whose functional classification is determined by that allele's core variants, not by this intronic tag. Carriers of the G allele at rs28695233 are not pharmacogenomically different from non-carriers, unless the haplotype they carry has independent functional variants.

Interactions

Because rs28695233 is a haplotype marker, its clinical significance is entirely determined by the other variants on the same chromosome. Knowing this variant in isolation provides no pharmacogenomic guidance. Complete CYP2D6 star allele diplotyping — incorporating core functional variants like rs3892097 (*4), rs1065852 (*10), rs28371725 (*41), rs16947 (R296C), rs5030655 (*6), and copy number analysis — is required to assign an activity score and metabolizer phenotype. rs28695233 can refine which sub-allele is present within that framework, but it does not change the functional tier.

PTP1B — the protein encoded by PTPN1 — functions as one of the most precisely validated negative regulators of insulin signaling in the human body. When insulin binds its receptor and triggers the tyrosine kinase cascade that drives glucose uptake into muscle and fat cells, PTP1B dephosphorylates the activated insulin receptor¹¹ dephosphorylates the activated insulin receptor
removes phosphate groups from tyrosine residues on the insulin receptor kinase domain, directly terminating downstream glucose-uptake signaling and its immediate substrates, ending each insulin pulse. In animal models, complete deletion of PTP1B²² complete deletion of PTP1B
PTP1B knockout mice remain lean on high-fat diets, show insulin hypersensitivity, and resist diet-induced obesity — providing proof-of-concept that PTP1B expression level is a key determinant of whole-body insulin sensitivity produces profound insulin hypersensitivity and resistance to obesity — establishing PTPN1 as both a drug target and a genetic risk locus for type 2 diabetes and metabolic syndrome.

rs3787345 is an intronic variant at GRCh38 chr20:50568886, situated within the ~100-kb PTPN1 linkage disequilibrium block³³ ~100-kb PTPN1 linkage disequilibrium block
A genomic region where recombination is rare, so all variants within it tend to be inherited together as a fixed haplotype package; every PTPN1 variant associated with insulin resistance and T2D falls within this same block that has been the subject of repeated association studies across European, Hispanic, and Asian cohorts. The variant itself does not alter the PTP1B amino acid sequence; its clinical significance comes from co-segregation with the risk haplotype across this regulatory block.

The Mechanism

The functional driver of this haplotype block is not rs3787345 itself but a functional insertion in the PTPN1 3'-UTR⁴⁴ functional insertion in the PTPN1 3'-UTR
A variant in the untranslated tail of the PTPN1 mRNA that stabilizes the transcript in skeletal muscle, increasing the amount of PTP1B protein produced per transcription event; this was identified by Bento et al. 2004 as the likely causal mechanism within the LD block that stabilizes PTPN1 mRNA in skeletal muscle, raising PTP1B protein levels. Higher PTP1B means each insulin pulse is terminated faster — the kinase window is shorter, less glucose transporter (GLUT4) is translocated to the muscle cell surface, and more circulating insulin is required to achieve the same glucose uptake. In the liver, PTP1B-impaired insulin signaling reduces LDL receptor recycling and increases VLDL assembly, connecting this locus to dyslipidemia independent of adiposity.

rs3787345 sits between rs941798 (chr20:50546698) and rs6020611 (chr20:50578070), two other well-characterized tag SNPs for this same haplotype block. All three variants — rs941798, rs3787345, and rs6020611 — carry the same biological message: minor allele carriage marks the risk haplotype with elevated PTP1B expression.

The Evidence

The haplotype block containing rs3787345 was systematically characterized by Bento et al. 2004⁵⁵ Bento et al. 2004
Bento JL et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes. 2004 Nov;53(11):3007-12, who genotyped 23 noncoding PTPN1 SNPs across 161 kb in Caucasian cohorts and found that all associated variants clustered in a single ~100-kb block with OR ~1.3 for type 2 diabetes and a population-attributable risk of 17–20%. Importantly, the functional mechanism — mRNA stabilization via a 3'-UTR variant — was directly demonstrated, distinguishing this from purely statistical associations.

Palmer et al. 2004⁶⁶ Palmer et al. 2004
Palmer ND et al. Association of PTPN1 gene polymorphisms with measures of glucose homeostasis in Hispanic Americans: the IRAS Family Study. Diabetes. 2004 Nov;53(11):3013-9 replicated these findings in 811 Hispanic Americans, showing that all 20 common PTPN1 LD-block SNPs were significantly associated with the insulin sensitivity index (p=0.003) and fasting glucose (p<0.001), extending the signal beyond European populations.

rs3787345 was included in the 14-SNP PTPN1 panel examined by Cheyssac et al. 2006⁷⁷ Cheyssac et al. 2006
Cheyssac C et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Med Genet. 2006;7:44, which studied 1,227 T2D cases and 1,047 controls in a French cohort. Haplotype analysis identified the CACG haplotype — incorporating multiple LD-block SNPs including rs3787345 — with marginal association with T2D (unadjusted p=0.02), while rs941798 and rs2426159 showed the most consistent individual associations with fasting insulin, HOMA-B, and lipid markers in normoglycemic controls.

The lipid connection was established by Bauer et al. 2010⁸⁸ Bauer et al. 2010
Bauer F et al. PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol. Eur J Cardiovasc Prev Rehabil. 2010;17(1):28-34, who found that minor allele carriers of closely co-segregating PTPN1 tag SNPs in this same block showed elevated LDL and total cholesterol specifically in lean men (BMI <26 kg/m²; p<0.05) — a BMI-stratified finding consistent with PTP1B-driven insulin resistance elevating cholesterol through direct hepatic mechanisms even in the absence of obesity.

Evidence level is moderate: the T2D signal for this entire LD block is replicated and mechanistically grounded, but the specific individual contribution of rs3787345 — as opposed to its co-varying block companions — has not been isolated at the genome-wide significance level. The signal is strongest at the haplotype level.

Practical Actions

Carrying the C allele at rs3787345 — particularly the CC genotype — marks the PTPN1 risk haplotype that confers chronically elevated PTP1B activity. The most actionable implications are metabolic monitoring and lifestyle choices that offset PTP1B-mediated insulin resistance.

Fasting insulin, HOMA-IR, and fasting LDL are the most informative biomarkers for this haplotype: PTP1B-driven insulin resistance can be present at normal body weight, so these labs add information beyond BMI. Resistance training and aerobic exercise directly downregulate PTP1B expression in skeletal muscle, providing a partially specific countermeasure. Reducing dietary saturated fat below 10% of calories limits hepatic LDL production through the PTP1B-impaired insulin signaling pathway.

Interactions

rs3787345 is in strong LD with rs941798, rs6020611, rs3787348, and rs914458 — all members of the same PTPN1 100-kb risk haplotype block. Carriers of the C allele at rs3787345 are likely co-carriers of the risk alleles at these other loci. If multiple PTPN1 tag SNPs are genotyped, the combination provides stronger haplotype resolution than any single variant alone. At the pathway level, PTPN1 interacts with the insulin receptor (INSR), IRS1, and PIK3R1 — downstream components of the insulin signaling cascade whose variants can compound PTP1B-driven impairment.

BTBD9 (BTB Domain Containing 9) encodes a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex¹¹ CUL3-RBX1 E3 ubiquitin ligase complex
A molecular machine that tags specific proteins for proteasomal degradation, controlling their cellular abundance. In the nervous system, this protein acts as a gatekeeper of iron homeostasis in dopaminergic circuits — the pathways that coordinate movement, motivation, and the rest–activity cycle. Dysfunction at BTBD9 disrupts iron storage, starves tyrosine hydroxylase of its required cofactor, and impairs dopamine synthesis — the sequence of events that produces the characteristic evening restlessness and periodic limb jerking of restless legs syndrome.

rs3923809 is an intronic variant within BTBD9 on chromosome 6p21.2. It is the most-cited index SNP for the BTBD9 RLS locus in the primary literature, and it sits in partial linkage disequilibrium with the related intronic variant rs9394502. Together they tag overlapping — but not identical — portions of the BTBD9 risk haplotype, meaning both variants contribute independent information about RLS susceptibility. The A allele at rs3923809 is the risk allele; despite being the GRCh38 reference sequence and the global majority allele (~68% frequency), carriers show consistently elevated rates of restless legs syndrome and periodic limb movements of sleep (PLMS) across multiple populations.

The Mechanism

BTBD9 functions as a Cullin-3 adaptor that ubiquitinates iron regulatory protein 2 (IRP2), targeting it for degradation. When BTBD9 is perturbed, IRP2 accumulates and suppresses ferritin expression, reducing cellular iron storage capacity. Because iron is a required cofactor for tyrosine hydroxylase²² tyrosine hydroxylase
The rate-limiting enzyme that converts L-tyrosine to L-DOPA, the immediate precursor of dopamine. Iron binds the enzyme's active site; low iron directly slows dopamine biosynthesis, reduced iron availability translates directly into reduced dopamine synthesis capacity in motor circuits.

In Drosophila, loss of the BTBD9 homologue reproduces all key RLS features: fragmented sleep, increased waking, and heightened locomotor restlessness. Restoring dopamine signalling in these flies rescues the motor phenotype, establishing dopamine deficiency — downstream of iron dysregulation — as the proximal cause of the RLS-like symptoms. Human carriers of BTBD9 risk alleles have measurably lower serum ferritin per risk allele, consistent with the IRP2/ferritin mechanism playing out systemically.

The Evidence

Moore et al. 2014³³ Moore et al. 2014
Moore H et al. Periodic leg movements during sleep are associated with polymorphisms in BTBD9, TOX3/BC034767, MEIS1, MAP2K5/SKOR1, and PTPRD. Sleep, 2014;37(9):1535-42 examined 1,090 participants from the Wisconsin Sleep Cohort with objective polysomnography, finding rs3923809 A allele the strongest genetic predictor of elevated PLMS (OR=1.65, P=1.5×10⁻⁸) — a genome-wide significant result from a community-based sample, not a clinical RLS cohort.

Winkelman et al. 2015⁴⁴ Winkelman et al. 2015
Winkelman JW et al. Genetic associations of periodic limb movements of sleep in the elderly for the MrOS sleep study. Sleep Med, 2015;16(11):1360-5 replicated this in 2,356 elderly men (OR=1.43, 95% CI 1.26–1.63 per A allele), demonstrating that the association persists in community populations not selected for RLS diagnosis, and that PLMS — often clinically silent — is independently heritable.

The RLS-specific signal was confirmed in multi-population replication. Kemlink et al. 2009⁵⁵ Kemlink et al. 2009
Kemlink D et al. Replication of restless legs syndrome loci in three European populations. J Med Genet, 2009;46(5):315-8 replicated the rs3923809 association across Czech, Austrian, and Finnish cohorts (649 cases, 1,230 controls; OR=1.58, P=4.11×10⁻⁵), concluding that "BTBD9 seems to be the most consistent in its effect on RLS across populations." Kim et al. 2013⁶⁶ Kim et al. 2013
Kim MK et al. Association of restless legs syndrome variants in Korean patients. Sleep, 2013;36(12):1787-91 extended this to an East Asian cohort (320 cases, 320 controls; OR 1.61–1.88, P<0.0001), confirming ethnic generalizability.

The mechanistic underpinning comes from Freeman et al. 2012⁷⁷ Freeman et al. 2012
Freeman A et al. Sleep fragmentation and motor restlessness in a Drosophila model of Restless Legs Syndrome. Curr Biol, 2012;22(12):1142-8, which demonstrated that BTBD9 controls brain dopamine levels and iron homeostasis via IRP2-mediated ferritin regulation — directly linking the genetic signal to the dopaminergic pathophysiology of RLS.

Practical Actions

The actionable intervention follows directly from the mechanism. Clinical guidelines for RLS recommend checking serum ferritin and targeting levels above 75 ng/mL — substantially higher than the 12 ng/mL general deficiency cutoff — because brain iron depletion drives symptoms even when hemoglobin is normal. For A allele carriers, this monitoring threshold is especially relevant: the BTBD9 iron-regulatory pathway is already compromised at baseline, making any additional iron deficit disproportionately impactful on dopamine synthesis.

AA homozygotes represent the most common risk group at this locus and should screen actively for RLS and PLMS, particularly as both are significantly underdiagnosed. PLMS in particular disrupts sleep architecture without triggering full awakening — many sufferers report non-restorative sleep without knowing why.

Interactions

rs3923809 and rs9394502 (also BTBD9, chr6:38,484,727) are in partial linkage disequilibrium. Carriers of both risk haplotypes show stronger periodic limb movement severity than either alone — a likely compound effect within the same gene. MEIS1 rs2300478 on chromosome 2p encodes a developmental transcription factor that is an independent RLS risk locus (OR ~1.7–1.9) and acts additively with BTBD9 variants; the combined MEIS1 + BTBD9 risk genotype is present in a significant fraction of clinically diagnosed RLS patients. MAP2K5 rs6494696 represents a third independent RLS locus identified in the Winkelmann 2007 GWAS that compounds further.

Your liver sits at the end of the lipoprotein remodeling pipeline. After peripheral tissues have stripped triglycerides from VLDL using lipoprotein lipase, the leftover remnant particles — along with large, buoyant HDL2 — return to the liver surface, where hepatic lipase (encoded by LIPC) performs the final cleanup: hydrolyzing residual triglycerides and phospholipids, converting HDL2 to smaller, denser HDL3 particles, and clearing IDL particles back into the LDL pool. This remodeling step shapes the HDL particle size distribution and clears atherogenic remnant lipoproteins from the bloodstream.

The rs4775065 variant sits in an intron of LIPC at chromosome 15q22 (GRCh38 position 58,509,744). The minor A allele (approximately 29% globally, with the G allele as the common protective form) has been linked to elevated susceptibility to the combined low HDL-C and coronary heart disease (CHD) phenotype. Notably, this is an intronic variant — it does not change the LIPC protein directly, but likely influences hepatic lipase expression or splicing through regulatory effects on the gene.

The Mechanism

Hepatic lipase¹¹ Hepatic lipase
HL; encoded by LIPC — a phospholipase and triglyceride lipase anchored to liver sinusoidal endothelium that clears IDL, VLDL remnants, and remodels HDL2 into HDL3 is central to the final step of lipoprotein remodeling. Variants that reduce HL activity preserve large HDL2 particles (raising nominal HDL-C) but also slow clearance of atherogenic remnant particles. Conversely, variants that raise HL activity produce smaller HDL3 and can lower the measured HDL-C.

The rs4775065 A allele sits in intron 1 of LIPC, adjacent to the well-characterized regulatory haplotype block containing rs1800588 (−514C>T) and rs2070895 (−250G>A). These promoter variants are in partial linkage disequilibrium with this locus and are established modulators of hepatic lipase activity. The rs4775065 intronic position suggests it may tag an expression-regulatory signal or be in LD with a functional regulatory element that has not yet been fully resolved.

The Peloso 2010 study found an intriguing dissociation: the A allele showed a very strong association with the combined low HDL-C + CHD case phenotype (OR 2.36 for heterozygotes, P=3.82×10⁻¹⁰ by 2df test), yet was not significantly associated with HDL-C levels alone when comparing controls stratified by their HDL. This suggests rs4775065 may influence CHD susceptibility through a pathway beyond simple HDL-C quantity — possibly affecting HDL particle function, remnant clearance, or triglyceride metabolism in a way not captured by the standard HDL-C number.

The Evidence

The primary evidence comes from a candidate-gene association study by Peloso et al.²² candidate-gene association study by Peloso et al. examining 60 metabolic-pathway genes in 699 men with low HDL-C and established CHD (VA-HIT trial) versus 705 CHD-free controls from the Framingham Offspring Study. Among all 60 candidate loci, rs4775065 in LIPC showed the single strongest association with case status: the A allele minor allele frequency was 0.33 in cases versus 0.23 in controls. Heterozygous AG individuals had an OR of 2.36 (95% CI 1.83–3.05), and the overall 2-degree-of-freedom genotypic test reached P=3.82×10⁻¹⁰. After lipid adjustment, the association remained significant (P=1.15×10⁻⁶), confirming that the variant's relationship to CHD risk is not fully mediated through measured lipid levels.

A Bayesian network analysis of lipoprotein biology³³ Bayesian network analysis of lipoprotein biology found rs4775065 associated with lower LDL-triglyceride levels (beta −0.06, P=0.039) and lower atherosclerosis odds (OR 0.67, P=0.037), a finding that appears to reflect the complex dual role of hepatic lipase — higher HL activity produces lower HDL-C (removing large HDL2) but also lowers triglyceride-rich remnant particles and may thus reduce atherogenesis. The directional complexity across studies reflects the fact that this variant modulates a pathway with effects on multiple lipoprotein fractions simultaneously.

The Feitosa et al. study⁴⁴ Feitosa et al. study of 591 NHLBI Family Heart Study families demonstrated that LIPC intron 1 variants modify HDL-C in a sex-specific fashion — with some variants showing female-predominant effects mediated through hormonal influences on hepatic lipase expression. rs4775065 was included as a tag SNP in this analysis, consistent with the broader LIPC intron 1 haplotype block.

The evidence level is moderate: the primary association study was not a genome-wide scan (it was a candidate-gene study with a pre-specified hypothesis about these 60 loci), but the statistical signal was exceptionally strong for a candidate-gene analysis, and the replication in independent contexts (Bayesian network, family study) supports the finding.

Practical Actions

For GG homozygotes (approximately 50% of people globally), the common LIPC allele at this locus is associated with standard hepatic lipase function. The CHD risk signal at this locus is not elevated.

For AG heterozygotes (approximately 41% globally), one A allele at rs4775065 is associated with approximately 2.4-fold higher odds of the combined low HDL-C and CHD phenotype compared to GG carriers. Monitoring triglycerides and HDL-C together — rather than treating HDL-C in isolation — is more informative, as the LIPC pathway affects both fractions. Omega-3 fatty acids (EPA/DHA) directly support hepatic lipase activity and improve HDL particle remodeling.

For AA homozygotes (approximately 8.5% globally), two A alleles carry the highest risk at this locus. A full lipoprotein assessment including triglycerides, non-HDL cholesterol, and ideally particle-size distribution (NMR lipoprofile or apoB) provides better cardiovascular risk stratification than HDL-C alone. Omega-3 supplementation at therapeutic doses and a lipid panel with triglycerides are the highest-yield interventions.

Interactions

rs4775065 lies within the broader LIPC regulatory haplotype that includes the promoter variants rs1800588 (−514C>T) and rs2070895 (−250G>A). These are in partial linkage disequilibrium, and their individual effects on hepatic lipase activity are mechanistically convergent. The separately catalogued LIPC eQTL rs1532085 acts on the same gene through overlapping regulatory architecture. When multiple LIPC variants are reported, rs1532085 (as the GWAS lead SNP with the strongest population-level signal) is the higher-powered estimate of the overall regulatory effect on HDL-C.

A gene-gene interaction between the LIPC locus and HMGCR (the statin target enzyme) has been documented in multi-ethnic cohorts, with the interaction explaining up to 1.1% additional HDL-C variance. Carriers of LIPC risk alleles who also carry HMGCR variants may have amplified or attenuated HDL effects beyond what either locus predicts independently.

CETP variants (particularly rs708272) interact additively with LIPC variants to raise HDL-C, but studies indicate only the CETP side of the interaction translates to reduced coronary artery disease events — underscoring that the source of elevated HDL (HL reduction versus CETP reduction) carries different cardiovascular implications.

Nuclear respiratory factor 1 (NRF1) sits at the heart of mitochondrial biogenesis, one step downstream from the master regulator PGC-1alpha. While PGC-1alpha (encoded by PPARGC1A) senses metabolic stress and initiates the biogenesis cascade, NRF1 translates that signal into action — binding directly to the promoters of nuclear genes that encode electron transport chain subunits, and activating TFAM, the protein that enters the mitochondrion to replicate and transcribe mitochondrial DNA. Without NRF1, the entire downstream half of the mitochondrial biogenesis program stalls.

The rs6949152 polymorphism lies within an intron of NRF1, on the plus strand of chromosome 7 at position 129,646,596 (GRCh38). The A allele is the major allele globally and the one associated with higher slow-twitch oxidative muscle fiber proportions and better aerobic training responses. The G allele is the minor risk allele, present in approximately 16% of Europeans, 19% of East Asians, and 39% of Africans. Though the molecular mechanism linking this intronic variant to NRF1 transcriptional output has not yet been fully characterized, intronic variants frequently influence mRNA splicing efficiency, regulatory element binding, or transcript stability.

The Mechanism

NRF1 activates transcription of nuclear genes encoding all five mitochondrial respiratory complexes (I–V), the assembly factors, and the mitochondrial transcription and replication machinery — specifically TFAM, TFB1M, and TFB2M. It also regulates TOMM20, the key translocase that imports nuclear-encoded proteins into the mitochondrial outer membrane. This positions NRF1 as the essential executor of PGC-1alpha's mitochondrial biogenesis program: PGC-1alpha coactivates NRF1 by directly binding it, and deletion of the N-terminal domain of NRF1 abolishes the PGC-1alpha effect entirely.

The oxidative (slow-twitch, MHC-I) muscle fiber type is the phenotype most clearly tied to NRF1 activity: slow-twitch fibers are dense in mitochondria, highly dependent on oxidative phosphorylation, insulin-sensitive, and fatigue-resistant. They are the cellular substrate of endurance capacity and long-term metabolic health. Studies across the rs6949152 literature consistently find the AA genotype associated with more MHC-I fibers and better aerobic training gains, suggesting that NRF1 expression or function is subtly higher in AA carriers — enabling fuller execution of the biogenesis program that builds and maintains oxidative muscle.

The Evidence

The clearest evidence comes from two independent study designs — a training intervention and a muscle biopsy study — converging on the same conclusion.

He et al.¹¹ He et al.
He Z et al. NRF-1 genotypes and endurance exercise capacity in young Chinese men. Br J Sports Med, 2008 studied 102 young Chinese male soldiers before and after 18 weeks of supervised endurance training (3 × 5000m runs per week at 95–105% ventilatory threshold). For rs6949152, a significant genotype-by-training interaction emerged for ventilatory threshold (p = 0.047), the key aerobic submaximal performance metric, with AA carriers showing meaningfully greater improvements over the training period. The companion SNP rs2402970 showed baseline effects on both ventilatory threshold (p = 0.004) and running economy (p = 0.027). VO2max trainability was not significantly associated with NRF1 haplotypes in this cohort, suggesting the variant's effect is concentrated in submaximal aerobic function rather than peak oxygen uptake.

Yvert et al.²² Yvert et al.
Yvert T et al. PPARGC1A rs8192678 and NRF1 rs6949152 Polymorphisms Are Associated with Muscle Fiber Composition in Women. Genes (Basel), 2020 performed vastus lateralis biopsies in 214 healthy Japanese subjects (107 men, 107 women, aged 19–79) and quantified myosin heavy chain (MHC) isoforms as direct markers of fiber-type composition. In women, the AA genotype was significantly associated with a higher proportion of MHC-I (slow-twitch oxidative fibers; p = 0.008) and a lower proportion of MHC-IIx (fast-twitch glycolytic fibers; p = 0.035). No significant associations were detected in men for rs6949152 alone. Combining PPARGC1A rs8192678 and NRF1 rs6949152 into a two-locus genotype score amplified the signal substantially: women with both AA genotypes showed the highest MHC-I proportion (p = 0.0007 for the combined score), while those carrying G alleles at both loci showed the lowest MHC-I. This additive effect strongly supports the hypothesis that the two SNPs act in the same PGC-1alpha→NRF1 pathway.

An extreme longevity case-control study³³ case-control study
Santiago C et al. Mitochondriogenesis genes and extreme longevity. Rejuvenation Research, 2013 examined rs6949152 among 107 Spanish centenarians versus 284 young controls across five genes in the PPARD–PPARGC1A–NRF–TFAM pathway. No significant between-group difference in rs6949152 allele frequency was detected. This null result in centenarians is consistent with the small per-allele effect size of this variant and the multifactorial nature of extreme longevity, and does not negate the functional associations in exercise and muscle-fiber studies at earlier life stages.

The neuroprotective importance of NRF1 protein levels (independent of rs6949152) is underscored by a 2024 study⁴⁴ 2024 study
Massaro M et al. Nuclear respiratory factor-1 (NRF1) induction drives mitochondrial biogenesis and attenuates amyloid beta-induced mitochondrial dysfunction and neurotoxicity. Neurotherapeutics, 2024 showing that NRF1 overexpression in neurons exposed to amyloid-beta restored mitochondrial mass, improved ATP synthesis, reduced ROS accumulation, and decreased neuronal death. This positions adequate NRF1 activity as relevant not only to muscle aging but to brain aging and neurodegeneration.

Practical Actions

The G allele's association with lower slow-twitch fiber proportions and blunted aerobic training response points to interventions that compensate at the level of mitochondrial function: strategies that either increase NRF1 activity (cold exposure, certain polyphenols) or that work downstream of NRF1 to support mitochondrial efficiency in the muscle fibers that are present. Given the strong interaction with PPARGC1A rs8192678 in the Yvert study, carriers of G alleles in both genes face a compounded deficit in the PGC-1alpha→NRF1→TFAM mitochondrial biogenesis axis.

Interactions

The most significant documented interaction is between rs6949152 and PPARGC1A rs8192678 (Gly482Ser). Both SNPs influence the same PGC-1alpha→NRF1→TFAM mitochondrial biogenesis pathway: rs8192678 impairs PGC-1alpha protein stability and MEF2 coactivation activity (upstream), while rs6949152 appears to reduce NRF1 transcriptional output (downstream). In the Yvert et al. biopsy study, the two-locus genotype score combining both risk alleles predicted MHC-I fiber proportion with p = 0.0007 in women — far stronger than either alone (p = 0.008 for NRF1 AA and p = 0.042 for PPARGC1A AA). Carriers of G alleles at both rs6949152 and the Ser allele at rs8192678 represent the lowest-NRF1-activity endpoint of the PGC-1alpha biogenesis axis. Combined action recommendations for this genotype pair should encompass both NAD+/SIRT1 activation of PGC-1alpha and direct NRF1 support through polyphenol supplementation (resveratrol, pterostilbene).

FOXO3 rs2802292 is a secondary interaction partner: the FOXO3 G-allele enhances mitochondrial quality control through mitophagy and stress-response pathways. In carriers of the NRF1 rs6949152 G allele who also lack the protective FOXO3 G-allele, both mitochondrial biogenesis and mitochondrial quality control are simultaneously compromised, a pattern of potential interest for age-related muscle and brain health.

Choline¹¹ Choline
An essential nutrient that serves as a building block for cell membranes (phosphatidylcholine), the neurotransmitter acetylcholine, and the methyl donor betaine is called "essential" for a reason: your body cannot make enough of it on its own. Almost all of it must come from food — unless you're a premenopausal woman with a working copy of PEMT²² PEMT
Phosphatidylethanolamine N-methyltransferase, the liver enzyme that converts PE to PC using methyl groups donated by SAM (S-adenosylmethionine) doing its job. The PEMT enzyme synthesizes phosphatidylcholine³³ phosphatidylcholine
The most abundant phospholipid in cell membranes and lipoproteins; it releases free choline when broken down, making PEMT the only significant route for endogenous choline production (PC) from phosphatidylethanolamine in the liver, releasing choline in the process. This is the body's only meaningful endogenous choline synthesis pathway.

The rs897453 variant (C→T) causes a valine-to-isoleucine substitution at position 95 of the PEMT protein. While this conservative missense change may have some direct effect on enzyme activity, the primary clinical signal from this SNP appears through tight linkage disequilibrium (r²=0.695) with rs4646343, a nearby variant that disrupts binding of the estrogen receptor and FOXA1⁴⁴ estrogen receptor and FOXA1
FOXA1 is a pioneer transcription factor that opens chromatin and allows the estrogen receptor to bind DNA; without FOXA1, estrogen cannot activate PEMT expression to the PEMT promoter, preventing hormone-inducible PEMT expression.

The Mechanism

Estrogen dramatically upregulates PEMT expression in the liver. This is why premenopausal women normally have a built-in advantage: their estrogen activates PEMT, allowing them to synthesize enough phosphatidylcholine endogenously to cover a significant portion of their choline needs. Men and postmenopausal women lack this hormonal boost and must obtain virtually all their choline from diet.

When the region spanning rs897453 and rs4646343 carries the risk haplotype, the estrogen receptor and FOXA1 pioneer factor cannot bind the PEMT promoter⁵⁵ cannot bind the PEMT promoter
Resseguie et al. showed that the risk allele failed to bind either the estrogen receptor or FOXA1 in chromatin immunoprecipitation assays. Without this estrogen-driven induction, premenopausal women lose their endogenous choline synthesis advantage and their dietary requirements approach those of men and postmenopausal women. The one-carbon methyl groups that PEMT uses (from S-adenosylmethionine, the universal methyl donor) are redirected or unavailable, compounding effects across the methylation network.

The Evidence

The landmark clinical evidence comes from a carefully controlled choline depletion trial by da Costa et al.⁶⁶ choline depletion trial by da Costa et al.
da Costa KA et al. Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB J, 2006: 57 healthy adults consumed a low-choline diet until they developed organ dysfunction or completed 42 days. Carriers of the risk allele in the PEMT promoter (rs12325817, in strong LD with rs897453) were dramatically more susceptible — 78% developed organ dysfunction including hepatic steatosis⁷⁷ hepatic steatosis
Fatty liver: excess fat accumulation in liver cells, detectable by liver enzyme elevation and imaging and muscle damage (odds ratio 25, p=0.002).

Resseguie et al. 2011⁸⁸ Resseguie et al. 2011
Resseguie ME et al. Aberrant estrogen regulation of PEMT results in choline deficiency-associated liver dysfunction. J Biol Chem, 2011 directly demonstrated the molecular mechanism: the risk haplotype prevents estrogen-receptor binding at the PEMT promoter, abolishing hormone-inducible PEMT expression and leaving carriers without the normally protective estrogen-driven choline synthesis.

Fischer et al. 2010⁹⁹ Fischer et al. 2010
Fischer LM et al. Dietary choline requirements of women: effects of estrogen and genetic variation. Am J Clin Nutr, 2010 confirmed that while most premenopausal women can tolerate low dietary choline without developing dysfunction (protected by estrogen-driven PEMT), women carrying PEMT risk variants lose this protection and require the same dietary choline as men.

A study by Seremak-Mrozikiewicz et al. 2018¹⁰¹⁰ Seremak-Mrozikiewicz et al. 2018
Seremak-Mrozikiewicz A et al. Importance of polymorphic variants of PEMT gene in the etiology of intrauterine fetal death. Eur J Obstet Gynecol Reprod Biol, 2018 found rs897453 among four PEMT polymorphisms studied in a Polish cohort, with other PEMT variants in the same region significantly associated with intrauterine fetal death, highlighting the importance of adequate choline during pregnancy.

Practical Actions

The core implication is straightforward: carriers of the T allele — especially premenopausal women and anyone who is pregnant — need to obtain more choline from diet and possibly supplementation because their liver makes less of it endogenously.

Dietary choline is concentrated in egg yolks (147 mg per large egg), beef liver (~418 mg per 3 oz), salmon, and soybeans. The adequate intake is 425 mg/day for women and 550 mg/day for men, but women carrying PEMT risk variants likely need the higher end of the range. During pregnancy, requirements rise to 450 mg/day or higher.

Phosphatidylcholine supplements (from sunflower or soy lecithin) provide a food-form choline that is well-tolerated, or choline bitartrate for a higher-dose option. CDP-choline (citicoline) is another form used for cognitive applications. Betaine (trimethylglycine) is a related methyl donor that can spare choline in one-carbon metabolism.

Because PEMT uses S-adenosylmethionine (SAM) as the methyl donor, adequate folate and B12 status supports the methylation capacity that feeds into PEMT. Carriers of MTHFR variants alongside rs897453 T alleles may face a compounded methylation burden.

Interactions

rs897453 sits in a haplotype block with rs4646343 and rs12325817 in the PEMT gene. The strongest documented gene-nutrient interaction is with estrogen status: the risk allele matters most in premenopausal women (who otherwise benefit from estrogen-driven PEMT induction) and during pregnancy (high choline demand). In men and postmenopausal women, the estrogen interaction is irrelevant, but the base reduction in PEMT activity still means lower endogenous PC synthesis.

PEMT requires SAM as the methyl donor for the three-step PE→PC methylation. Any variant that impairs SAM availability — including MTHFR C677T (rs1801133) or MTRR variants — will reduce the substrate available for PEMT, compounding the effect of rs897453 on net phosphatidylcholine output. Individuals carrying risk variants in both pathways may have particularly elevated choline requirements.

PEMT V175M (rs7946), a separate coding variant in the same gene, showed association with neural tube defect risk in the Mills et al. 2014 study — though the two variants have different functional mechanisms and should be interpreted independently.

Tucked within TH2LCRR — T helper type 2 locus control region associated RNA — a long noncoding RNA¹¹ long noncoding RNA
lncRNA; a class of RNA molecules longer than 200 nucleotides that do not encode proteins but instead regulate chromatin structure, transcription, and gene expression in the cells where they are expressed that sits at the genomic address where some of the most replicated allergy genetics live — chromosome 5q31.1, position 132,648,366 (GRCh38). This locus is flanked upstream by RAD50²² RAD50
RAD50 double-strand break repair protein; at 5q31, RAD50's intronic sequences house the Th2 locus control region (TH2-LCR), a cluster of regulatory elements that coordinate IL-4, IL-5, and IL-13 expression in Th2-committed immune cells and downstream by IL13 and IL4 — the principal Th2 cytokines responsible for IgE class switching, airway remodeling, and eosinophil recruitment. rs2158177 lies within TH2LCRR's intronic sequence, embedded in one of the most replicated immune-regulation loci in human genetics.

The Mechanism

The intergenic and intronic space between RAD50 and IL13 is home to the Th2 locus control region (TH2-LCR)³³ Th2 locus control region (TH2-LCR)
a cluster of DNase I hypersensitive sites (RHS4–RHS7) that act as long-range chromatin enhancers; when a naive T cell commits to the Th2 lineage, these elements loop chromosomally to simultaneously activate IL-4, IL-5, and IL-13 transcription; allele-specific variants in RHS7 alter DNA methylation at the IL13 promoter — a set of chromatin regulatory elements that collectively determine how vigorously IL-4, IL-5, and IL-13 are transcribed when the immune system encounters allergens and shifts to a Th2 response.

TH2LCRR itself is a lncRNA whose expression is regulated by this same enhancer machinery. Li et al. (2022)⁴⁴ Li et al. (2022)
Li YK et al. Am J Respir Cell Mol Biol 2022; convergent evidence study combining GWAS data, eQTL analysis, and chromosomal conformation capture in human bronchial epithelial cells demonstrated that TH2LCRR expression is significantly elevated in asthma patients and is dependent on the genotype at this locus — with an enhancer containing functional SNPs physically looping to the TH2LCRR promoter, driving expression. rs2158177 is an intronic variant within TH2LCRR, positioned approximately 11 kb from rs2040704 (the established enhancer hub variant at the same locus). Whether rs2158177 itself has independent functional effects or tags the same regulatory haplotype as nearby variants remains to be fully resolved, but population data from the GWAS Catalog places its G allele (European frequency ~21%) in association with elevated blood eosinophil counts (beta=0.064, p=3×10⁻³⁸) — a direct readout of Th2/atopic activation state.

The Evidence

The 5q31 RAD50/TH2LCRR/IL13 locus has genome-wide significance for atopic disease in multiple independent cohorts. A GWAS of childhood-onset atopic dermatitis⁵⁵ GWAS of childhood-onset atopic dermatitis
Weidinger et al. Hum Mol Genet 2013; four loci identified: EDC on chromosome 1, LRRC32 on chromosome 11, RAD50/IL13 on chromosome 5, and MHC on chromosome 6 — Weidinger et al. (2013) — identified the RAD50/IL13 locus as one of only four genome-wide significant loci for childhood AD. Cross-ethnic replication from Jiang et al. (2017)⁶⁶ Jiang et al. (2017)
Jiang XY et al. Asian Pac J Allergy Immunol 2017; 3,013 AD cases and 5,483 controls from the Chinese Han population; two loci — 5q31 and 5q22.1 — both associated with JAK-STAT signaling pathway — analyzing 3,013 atopic dermatitis cases and 5,483 controls in a Chinese Han cohort — confirmed the same 5q31 locus via rs2158177 specifically (OR=1.15, P=1.08×10⁻³), with the dominant model reaching P=3.75×10⁻³. Both loci were functionally annotated to the JAK-STAT signaling pathway, confirming the immune-regulatory context.

A smaller Chinese Han asthma study⁷⁷ Chinese Han asthma study
Liang et al. 2015; 400 asthma cases and 200 controls in Qingdao; assessed both IL-13 and TNF-alpha polymorphisms found an opposite-direction signal for GG homozygotes specifically — fewer GG individuals in cases versus controls (OR=0.31). This result, from a sample a fraction of the size of the AD and eosinophil studies, likely reflects limited power, haplotype context differences between asthma and AD endpoints, or both; the eosinophil GWAS signal (p=3×10⁻³⁸, N=hundreds of thousands) and the AD replication (OR=1.15) in the same direction as the broader 5q31 evidence represent substantially stronger evidence for G allele risk.

Fine-mapping in >1,300 German children⁸⁸ >1,300 German children
Sharma et al. Allergy 2014 confirmed 5q31 as one of three major IgE-regulating loci — alongside 1q23 (FCER1A, the high-affinity IgE receptor) and 12q13 (STAT6) — with carriers of risk alleles at all three loci showing fourfold elevated IgE. The review by Potaczek & Kabesch (2012)⁹⁹ review by Potaczek & Kabesch (2012)
Potaczek DP, Kabesch M. Clin Exp Allergy 2012 places 5q31 within the consensus six-locus framework for IgE genetic architecture.

Practical Implications

The G allele at rs2158177 is a marker of elevated Th2 locus activity — the same biological axis that dupilumab (anti-IL-4Rα), tralokinumab (anti-IL-13), and anti-IL-5 biologics target. For carriers of one or two G alleles who develop refractory atopic conditions, the upstream genetic basis in IL-4/IL-13/IL-5 production provides mechanistic rationale for biologic therapy targeting this axis.

The eosinophil count elevation (beta=0.064 per G allele copy in the large GWAS) means G carriers will tend to have slightly higher baseline eosinophil counts — a readout of Th2 activation. This is clinically useful: an eosinophil count above 300 cells/µL in a symptomatic patient with G alleles supports Th2-driven inflammation and biologic candidacy.

Interactions

rs2158177 is in the same chromosomal region as rs2040704 — approximately 11 kb apart within the 5q31 TH2-LCR — and likely tags the same or an overlapping regulatory haplotype. Both variants are associated with elevated Th2 output; carrying risk alleles at both loci represents the highest local Th2-amplifying burden.

The IL13 coding variant rs20541 (R130Q), ~20 kb downstream, reduces IL-13 affinity for its decoy receptor, increasing IL-13 bioavailability independently of production. The combination of this production-amplifying locus (rs2158177/rs2040704 G allele) with reduced clearance (rs20541 A allele) constitutes a mechanistically coherent double hit on sustained IL-13 signaling.

Carriers who also have rs1801275 (IL-4Rα R576Q) or rs1837253 (TSLP upstream) risk alleles face additional Th2 amplification from receptor signaling efficiency and upstream alarmin cytokine production respectively — the most eosinophilic, IgE-high phenotype emerges from compound risk across production, clearance, receptor, and alarmin axes.